Grŵp Strategaeth Meddyginiaethau Cymru Gyfan All Wales Medicines Strategy Group



Final Appraisal Recommendation

Advice number: 0622 - March 2022

Adalimumab (Humira®) 40 mg/0.4 ml and 80 mg/0.8 ml solution for injection in pre-filled pen or syringe

Submission by AbbVie Ltd

Recommendation of the All Wales Medicines Strategy Group

Adalimumab (Humira®) is recommended as an option for use within NHS Wales for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6- mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.

Additional note(s):

 See NICE guidance for adalimumab (Humira®) for the treatment of moderately to severely active ulcerative colitis in adults (TA329, originally published February 2015).

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 4526), which includes the All Wales Therapeutics and Toxicology Centre (AWTTC) assessment, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 0622:

Adalimumab (Humira®) 40 mg/0.4 ml and 80 mg/0.8 ml solution for injection in pre-filled pen or syringe. March 2022

